Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Cash Position

<< Previous

Bullboard Posts

Next >>

Comment by SomeBroon Oct 18, 2021 10:49am

260 Views

Post# 34017882

RE:Cash Position

Yea I'm just keeping my money in and considering it lost at this point. Hoping for a future return somehow, but with Dan just seems like a slimeball only concerned with misleading shareholders, filling his own greedy pockets and pleasing his golddigging wife. The guy has got to go, he's been leading investors on for too long.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?